Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025

Summary by AI BETAClose X

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) presented compelling Phase 2 VIVIAD study data for varoglutamstat at ASN Kidney Week 2025, demonstrating its potential to stabilize and improve kidney function, as measured by eGFR values. Analyses from the 259-patient VIVIAD Phase 2b study revealed a statistically significant correlation between a decrease in the anti-inflammatory biomarker pE-CCL2 at week 48 and a positive eGFR slope, indicating improved kidney function. These results support varoglutamstat's mechanism of action for kidney disease. Vivoryon plans a dedicated Phase 2b study in advanced diabetic kidney disease (DKD) stage 3b/4, but its initiation and all future studies are contingent upon securing additional funding or partnerships, which could impact future development timelines and stock performance.

Disclaimer*

UK 100

Latest directors dealings